Biopharmaceutical company AstraZeneca has announced a collaboration with analytics firm SAS to leverage the power of artificial intelligence (AI) in its drug discovery efforts. The partnership aims to transform how clinical data is utilized to support a patient-centric approach and expedite the delivery of medicines.
SAS will provide its data analytics suite and AI capabilities to assist AstraZeneca in the search for new drug candidates. By leveraging industry-leading analytics and AI, the companies aim to revolutionize the analysis of clinical and patient data, optimize trial designs in a rapidly evolving regulatory environment, and accelerate the reporting and submission process.
The collaboration also seeks to enhance the capacity, automation, interoperability, and flexibility of AstraZeneca’s data analysis capabilities. It will enable the integration and analysis of diverse patient data sources, including wearables, sensors, and precision medicine, as part of the submissions process. The goal is to enable AstraZeneca to quickly identify new insights and potential breakthroughs in drug development.
Christopher Miller, Vice President for Biometrics at AstraZeneca, expressed excitement about the collaboration, stating that it supports the company’s patient-focused approach and commitment to delivering medicines faster than ever before. He emphasized that the partnership with SAS will introduce new ways of working and incorporate innovative technologies and trial models to accelerate AstraZeneca’s portfolio.
SAS, a global leader in analytics, has been steadily investing in AI over the past two years. The company’s involvement in this transformation program with AstraZeneca builds upon their long-standing partnership. Bryan Harris, Chief Technology Officer at SAS, expressed enthusiasm about deepening the collaboration, acknowledging that while progress has been made, there is still much more to explore and achieve together.
The financial terms of the deal have not been disclosed. This collaboration reflects AstraZeneca’s commitment to harnessing the power of AI and advanced analytics to revolutionize the drug discovery process and ultimately improve patient outcomes. By leveraging the capabilities of SAS, AstraZeneca aims to accelerate the development of life-saving medicines and enhance its clinical data management.
